PubRank

A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

Clinical Trial ID NCT02048488

PubWeight™ 15.19‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02048488

Top papers

Rank Title Journal Year PubWeight™‹?›
1 ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014 1.48
2 Novel ALK inhibitors in clinical use and development. J Hematol Oncol 2015 1.24
3 Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol 2015 1.24
4 TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2014 1.19
5 Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol 2014 1.17
6 A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol 2014 0.93
7 Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget 2015 0.91
8 Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Cancers (Basel) 2015 0.90
9 Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med 2015 0.88
10 NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016 0.87
11 ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol 2016 0.86
12 Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol 2016 0.79
13 The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol 2014 0.78
14 Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol 2015 0.76
15 Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. J Thorac Dis 2016 0.75
16 Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options. Cancer Biol Med 2016 0.75
Next 100